Development Of AD214 A Novel Anti-fibrotic Treatment For Advanced Age Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$687,994.00
Summary
Age related macular degeneration remains the leading cause of blindness in this and other industrialised countries. Although treatment is available for an advanced form of the disease, many do not respond, or lose significant amounts of vision with long term treatment. This proposal will provide critical data for commericalizing a novel therapy called an i-body (AD214), that reduces vision loss in this disease by blocking the formation of scarring with reduced need for injections.
Huntington’s disease is a devastating neurological disorder, with no drugs currently available to cure or treat the underlying cause. Our recent laboratory work on a drug called PBT2 was the foundation of a encouraging clinical trail for this disease. Here, we propose to investigate a drug called Zn(DTSM) for this disease, which has similar properties to PBT2, but we expect will have a greater effect.